Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

Rhea-AI Summary

Pluri (Nasdaq/TASE: PLUR) reported that its majority-owned food-tech company Ever After Foods has acquired Belgium-based Fishway BV, a biotechnology company specializing in aquatic cell biology and animal-component-free (ACF) media for the cultivated-protein industry.

The deal adds Fishway’s aquatic cell biology know-how, ACF media development capabilities and an established scientific presence in Belgium to Ever After Foods’ open, species-agnostic cultivated-protein manufacturing platform. According to Pluri, this supports Ever After Foods’ strategy to broaden its cultivated-protein applications and better support food and ingredient companies moving from development to scalable production.

In parallel with the acquisition, Ever After Foods secured an additional $2 million strategic investment through a simple agreement for future equity (SAFE) to fund ongoing platform development and commercialization activities.

Positive

• Fishway acquisition adds aquatic cell biology and ACF media capabilities to Ever After Foods’ platform
• $2 million strategic investment via SAFE to support development and commercialization
• Acquisition provides Ever After Foods with an established scientific presence in Belgium, expanding its European footprint

Negative

• None.

Key Figures

Strategic investment: $2 million

Strategic investment

$2 million

In connection with the Fishway acquisition

Previous Acquisition Reports

2 past events · Latest: Apr 28

Same Type 2 events

1. Apr 28

   Kokomodo acquisition

   24h Move

   -13.7%

   Pluri acquired approximately 71% of cultivated-cacao company Kokomodo for $4.5 million.

2. Jan 23

   Cacao acquisition investment

   24h Move

   +6.4%

   Pluri secured $6.5 million investment while acquiring a 71% Kokomodo stake.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

safe agreement, animal-component-free (acf) media, aquatic cell biology, bioprocess engineering

4 terms

safe agreement financial

"through a simple agreement for future equity (“SAFE Agreement”)"

A SAFE (Simple Agreement for Future Equity) is a contract investors use to provide capital to a private company now in exchange for the right to receive shares later, typically when the company raises a priced round or is sold. Think of it like a voucher that converts into stock at a future financing event according to pre-set terms (such as a valuation cap or discount). It matters to investors because SAFEs determine how much ownership and dilution early backers will receive once the company’s equity is formally issued, affecting potential returns and the company’s capitalization structure.

animal-component-free (acf) media technical

"specializing in aquatic cell biology and animal-component-free (ACF) media development"

Cell culture media labeled animal-component-free (ACF) are nutrient solutions formulated without any materials derived from animals, such as serum, gelatin, or animal-derived growth factors. Like a recipe that avoids any animal ingredients, ACF media are used to grow cells with fewer risks of animal-borne contaminants and more consistent composition, which matters to investors because it affects manufacturing scale, regulatory acceptance, product reproducibility, and supply-chain reliability in biotech and pharmaceutical production.

aquatic cell biology technical

"specializing in aquatic cell biology and animal-component-free (ACF) media development"

Study of the structure, function and behavior of cells that live in water environments—from single-celled microbes to the cells of fish, shellfish, algae and aquatic plants. It looks at how those cells grow, respond to stress, exchange nutrients and interact with pollutants or pathogens, like examining the bricks and wiring of buildings that live underwater. For investors, it matters because findings can drive developments in aquaculture, environmental monitoring, marine biotechnology, drug discovery, and sustainable products tied to water-based organisms.

bioprocess engineering technical

"integrating biology, media, bioprocess engineering and advanced manufacturing"

The engineering discipline that designs, optimizes, and scales the systems used to make biological products—like vaccines, enzymes, or cell therapies—using living cells, microbes, or biological molecules. Think of it as turning a recipe developed in a lab into a reliable factory process, controlling conditions, equipment, and quality so production runs safely, efficiently, and consistently. It matters to investors because bioprocess choices affect manufacturing costs, time to market, regulatory approval, and product supply reliability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence

• Ever After Foods secures an additional $2 million strategic investment supporting ongoing platform development and commercialization activities.
  
  

HAIFA, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri”), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its majority-owned food-tech portfolio company, Ever After Foods Ltd. (EAF), an industrial technology company developing an open manufacturing platform for cultivated-protein, has acquired Fishway BV, a Belgium-based biotechnology company specializing in aquatic cell biology and animal-component-free (ACF) media development.

EAF provides an open manufacturing platform for the cultivated-protein industry, integrating biology, media, bioprocess engineering and advanced manufacturing. The acquisition adds Fishway’s know-how and related scientific capabilities and expertise in aquatic cell biology and ACF media development to EAF’s bioprocess and manufacturing platform and supports EAF’s strategy to expand its capabilities with a broader range of cultivated-protein applications. Fishway also gives EAF an established scientific presence in Belgium, expanding its European footprint and adding specialized capabilities to its platform, thus strengthening EAF's ability to work with food and ingredient companies as they move from development toward scalable production.

In parallel with the transaction, EAF should an additional $2 million strategic investment through a simple agreement for future equity (“SAFE Agreement”) being entered into in connection with the acquisition of Fishway, to support ongoing platform development and commercialization activities.

"The next phase of the cultivated protein industry will increasingly depend on integrating complementary technologies into scalable industrial platforms. Fishway adds strong capabilities in aquatic cell biology and animal-component-free media that complement Ever After Foods' production platform and expand the range of applications we can support. This is an important first step in executing our broader platform strategy,” said Eyal Rosenthal, CEO of Ever After Foods.

"Ever After Foods shows how Pluri's cell-based technology and manufacturing experience can create value and be applied to practical solutions for the food industry," said Yaky Yanay, President and Chief Executive Officer of Pluri. "Fishway brings complementary science, talent and a European base to EAF. We believe this is a focused strategic step that strengthens the platform and EAF's ability to support customers as they move toward commercial-scale cultivated protein production."

About Ever After Foods

Ever After Foods is an industrial technology company building the next generation of protein manufacturing infrastructure. Its open, species-agnostic platform integrates biology, media, bioprocess engineering and advanced manufacturing technologies into scalable production systems that enable food and ingredient companies to produce next-generation proteins efficiently, sustainably and at industrial scale.

About Fishway

Fishway is a Belgium-based cell-biology developer, specializing in aquatic cell lines and animal-component-free (ACF) media for the cultivated-protein industry.

About Pluri Inc.

Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. Pluri's technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges, from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri currently operates in the regenerative medicine, longevity, foodtech and agtech fields and offers Contract Development and Manufacturing Organization (CDMO) services. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.

Safe Harbor Statement

This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the additional capabilities of EAF’s platform following the acquisition; the closing of the transaction; the potential benefits of the transaction, the potential to receive an additional $2 million investment through a SAFE Agreement; EAF’s European footprint expansion; that Pluri’s technology and experience will create value and will be applied to practical solutions for the food industry; and that EAF’s ability to support customers as they move toward commercial-scale cultivated protein production will strengthen. These forward-looking statements are based on the current expectations of management only and are subject to factors and uncertainties that could cause actual results to differ materially, including: changes in technology and market requirements; the Company may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri's reports filed from time to time with the Securities and Exchange Commission.

Contact

investor.relations@pluri-biotech.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pluri (PLUR) announce about Ever After Foods and Fishway on August 17, 2026?

Pluri announced that Ever After Foods acquired Belgium-based Fishway BV and secured a $2 million strategic investment. According to Pluri, the deal adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence to Ever After Foods’ cultivated-protein platform.

How much new funding did Ever After Foods raise in the Pluri (PLUR) Fishway transaction?

Ever After Foods raised an additional $2 million strategic investment alongside the Fishway acquisition. According to Pluri, this funding was provided through a simple agreement for future equity (SAFE) to support ongoing platform development and commercialization activities in cultivated-protein manufacturing.

How does the Fishway acquisition benefit Ever After Foods’ cultivated-protein platform for Pluri (PLUR)?

The Fishway acquisition adds aquatic cell biology and animal-component-free media expertise to Ever After Foods’ platform. According to Pluri, these capabilities broaden cultivated-protein applications and strengthen support for food and ingredient companies moving from development toward scalable industrial production.

What strategic role does Fishway’s European presence play for Ever After Foods and Pluri (PLUR)?

Fishway provides Ever After Foods with an established scientific presence in Belgium, expanding its European footprint. According to Pluri, this added base and specialized capabilities enhance Ever After Foods’ ability to work with European food and ingredient companies on cultivated-protein scale-up.

What is Ever After Foods’ business focus within Pluri’s (PLUR) portfolio?

Ever After Foods develops an open, species-agnostic manufacturing platform for cultivated-protein production. According to Pluri, it integrates biology, media, bioprocess engineering and advanced manufacturing to help food and ingredient companies produce next-generation proteins efficiently, sustainably and at industrial scale.

What does Fishway BV contribute scientifically to Ever After Foods and Pluri (PLUR)?

Fishway contributes expertise in aquatic cell lines and animal-component-free media for the cultivated-protein industry. According to Pluri, this scientific know-how is integrated into Ever After Foods’ bioprocess and manufacturing platform to expand the range of cultivated-protein applications it can support.